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Abstract
Domesticated animals have a large variety of antimicrobial peptides that serve as natural innate barriers limiting microbial
infection or, in some instances, act as an integral component in response to inflammation or microbial infection. These peptides
differ in size, composition, mechanisms of activity and range of antimicrobial specificities. They are expressed in many tissues,
polymorphonuclear leukocytes, macrophages and mucosal epithelial cells. There is a small group of anionic antimicrobial peptides
found in ruminants and a much larger group of cationic antimicrobial peptides found in all domesticated animals. The cationic
peptides include linear, helical peptides, linear peptides rich in proline and cysteine-stabilized peptides with a b-sheet and are
commonly referred to as cathelicidins and defensins. These peptides are generally broad-spectrum for Gram-positive bacteria,
Gram-negative bacteria and fungi (e.g. myeloid antimicrobial peptides, a-, b-defensins, and protegrins) or are specific to one of these
groups (e.g. porcine cecropin P1, Bac5, Bac7, PR-39 and prophenin).
Published by Elsevier B.V.
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1. Introduction
The use of low levels of antibiotics as growth
promotors in animal feeds [1/3] and the extensive use
of antibiotics to treat human or animal infections [4/6]
are thought to be the cause of an alarming increase in
antibiotic resistance among Gram-negative, Gram-posi-
tive and fungal pathogens, a highly debated and
controversial issue [7,8]. Bacterial resistance to many
classes of antibiotics is becoming a major clinical
problem [9,10]. Therefore, the search continues for
new antibiotics that are active in vivo, are fast acting
and broad-spectrum, do not induce bacterial resistance
and have limited side effects. Synthetic congeners of
natural antimicrobial peptides are good candidates. In
addition to the properties described above, they have
low MICs and broad-spectrum activity in both low and
high ionic strength conditions [11], neutralize LPS [12],
promote wound healing [13,14], and have synergistic
activity with conventional antibiotics [15]. Very few side
effects have been reported.
A large variety of antimicrobial peptides are found in
domesticated animals (Table 1). They are expressed in
many tissues, polymorphonuclear leukocytes, macro-
phages and mucosal epithelial cells (Table 2). These
peptides are broad-spectrum with potent antimicrobial
activity against both human and veterinary pathogens.
Domesticated animals serve as a valuable source of
antimicrobial peptides. They also serve as models to test
the efficacy, wound healing effects, and immunological
properties of antimicrobial peptides. Antimicrobial
peptides are conserved in their structure, function and
mechanisms of action, and thus it is attractive to
speculate that synthetic antimicrobial peptides or their
congeners might be used to prevent or treat infections.
As we begin to identify the mechanisms to initiate
synthesis and release of antimicrobial peptides, it may
also be possible to find ways to trigger their production
* Corresponding author. Tel.: /1-515-663-7980; fax: /1-515-663-
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in animals at stressful times when they are most
susceptible to microbial infection (e.g. during transport,
castration, weaning, etc.). In this review, an updated list
of antimicrobial peptides found in domesticated animals
is presented, including sites of antimicrobial peptide
production, antimicrobial activity, and their potential
use for therapeutic treatment of infectious disease.
2. Types of antimicrobial peptides and sites of
antimicrobial expression
Antimicrobial peptides have been a popular topic of
research and over 750 eucaryotic antimicrobial peptides
have been reported (http://www.bbcm.univ.trieste.it//
tossi/pag5.htm). These peptides are grouped according
to similarities in charge, sequence homology, functional
similarity and 3-dimensional structure [16/20].
2.1. Anionic antimicrobial peptides
In 1992, ovine pulmonary surfactant was reported to
kill Mannheimia haemolytica , Escherichia coli and
Klebsiella pneumoniae [21]. The antimicrobial activity
was due to three small (721.6/823.8 Da) anionic
peptides: H-GDDDDDD-OH, H-DDDDDDD-OH
and H-GADDDDD-OH [22]. These peptides required
zinc for maximal activity [22] and were very similar to
the charge-neutralizing propeptides of larger zymogens
[23], which when synthesized were also antimicrobial
[24]. In addition to their innate antimicrobial activity,
anionic antimicrobial peptides may also have a regula-
tory role in pulmonary metabolism. Their structure is
similar to the charge-neutralizing propeptides of Group
I serine proteases, and they may be capable of regulat-
ing, via negative feedback inhibition, the activity of
pulmonary enzyme systems. Anionic peptides have been
shown to be trypsin inhibitors.
Recently, anionic peptides have also been detected in
cattle [25]. Anionic peptide concentration in bronchoal-
veolar lavage fluid from neonatal calves was found to be
about threefold higher than that in adult cattle. How-
ever, bronchoalveolar lavage fluid from neonates had
significantly less antimicrobial activity against M. hae-
molytica compared with the activity of bronchoalveolar
lavage fluid from adults [25].
In Western blots, antibody to anionic peptides
detected larger zymogens in solubilized turbinate, tra-
cheal, pulmonary tissue, liver, and small intestine [26].
In pulmonary tissue sections, antibodies identified
accumulated protein in the apical cytoplasm of the
bronchial and bronchiolar epithelium, in the cytoplasm
of pulmonary endothelial cells and in an occasional
alveolar macrophage [26].
The mechanism of bacterial killing by anionic pep-
tides is not known. Anionic peptides require zinc for
maximal activity [22,27/29] and form a complex with it
[30]. Therefore, it is attractive to speculate that zinc may
form a cationic salt bridge that allows the peptide to
overcome the net negative charge on the microbial
surface. The peptide then penetrates the outer mem-
brane without inducing any morphological changes [22].
Once in the cytoplasm, anionic peptides may then attach
to ribosomes and inhibit ribonuclease activity similar to
that seen with polymers of aspartic acid [31/33].
Ultimately, the cytoplasmic protein precipitates and
settles out, suggesting an internal mechanism of protein
inactivation (Fig. 1). Killing occurs within 30 min [22].
2.2. Cationic antimicrobial peptides
Cationic antimicrobial peptides are very common in
domesticated animals and vary considerably in their
composition, structure and distribution among species
[18,20]. They occur in three principle categories
[16,17,19,20]: linear, helical peptides (Table 3), linear
peptides rich in proline (Table 3) and cysteine-stabilized
peptides with a b-sheet (Table 4). Within each of these
groups are cathelicidins [34,35], peptides that differ
greatly in their sequences, structures and sizes. All
have a high content of the basic amino acids arginine
Table 1
Classes of antimicrobial peptides from domestic animals
Class of peptide General antimicrobial activity
(references)
Anionic peptides
Rich in aspartic and glutamic
acids
Gram-negative, Gram-
positive bacteria [22,24]
Cationic peptides
Linear and amphipathic helical
molecules
Seminalplasmin Broad-spectrum [121]
Myeloid antimicrobial peptides
(PMAP, SMAP, BMAP)
Broad-spectrum [11,41]
Porcine cecropin P1 Gram-negative, some Gram-
positive bacteria [37,39]
eCATH-1, eCATH-2, eCATH-3 Broad-spectrum [35,50]
Linear peptides rich in proline
Bac5 and Bac7 Gram-negative bacteria [20] but
can be broad spectrum [54]
PR-39 Gram-negative bacteria [20,59]
Indolicidin (rich in tryptophan) Gram-negative, Gram-positive
bacteria [69]
Prophenin (rich in proline and
phenylalanine)
Gram-negative bacteria [67]
Cysteine-stabilized sheet mole-
cules
a-, b-Defensins Broad-spectrum [20,77,81,122]
Rhesus theta defensin-1 (RTD-1) Broad-spectrum [94]
Protegrins Broad-spectrum [41,97]
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and lysine [11,36]. They have a common N-terminal
preproregion of about 100 residues that is homologous
to the cysteine protease inhibitor cathelin [13]. This
conserved region also serves as the target for searches of
new cathelicidins. The highly variable C-terminus con-
tains the cationic antimicrobial domain. After synthesis,
the C-terminus is cleaved off, forming the mature
antimicrobial peptide.
Table 2
Antimicrobial proteins in animals
Animal
species
Peptide Tissue/cell type References
Cattle Anionic peptides [25]
BNBD-1/3, 6/11, 13 neutrophils [77/80]
BNBD-4 bone marrow, distal small intestine, trachea, lung, spleen, colon, bovine alveolar
macrophages
[78,80]
BNBD-5 bovine alveolar macrophages [80]
BNBD-12 bone marrow, distal small intestine, trachea, colon [78]
TAP nasal epithelium, trachea, bronchioles, alveolar macrophages [81,82,84]
LAP alveolar macrophages, tongue [80,83]
EBD alveolar macrophages, intestine [80,123]
BMAP27 bone marrow myeloid cells [34,124]
BMAP28 bone marrow myeloid cells [34,124]
BMAP34 neutrophils, bone marrow myeloid cells, spleen, testis [34,49]
Bac5, Bac7 neutrophils [34,53,56,125]
Indolicidin neutrophils [34,69/71]
Dodecapeptide neutrophils [126,127]
Sheep Anionic peptides turbinates, trachea, pulmonary tissue, liver, small intestine [22,26]
Sheep BD-1 tongue, trachea, rumen, reticulum, omasum, colon [86]
Sheep BD-2 ileum, colon [86]
SMAP28 neutrophils [45,46]
SMAP29 bone marrow myeloid cells [11,43/46]
SMAP34 bone marrow myeloid cells [11,43/46]
OaBac5a, b neutrophils [54]
OaBac6 sheep genomic library [128]
OaBac7.5 bone marrow myeloid cells [44,128]
OaBac11 sheep genomic library [128]
Dodecapeptide bone marrow myeloid cells [44]
Goats Goat BD-1 tongue, respiratory tract [88]
Goat BD-2 intestine [88]
ChBac5 neutrophils [54]
Pigs Porcine BD-1 respiratory tract, digestive tract, thymus, spleen, lymph node, brain, liver, kidney, urinary
bladder, testis, skin, heart, muscle, bone marrow, neutrophils, alveolar macrophages,
umbilical cord
[129]
PMAP23 bone marrow myeloid cells [40,42,60]
PMAP36 bone marrow myeloid cells [40,41,130]
PMAP37 bone marrow myeloid cells [60,131]
PR-39 intestinal epithelium, neutrophils [38,58,62,132]
bPR-39 porcine liver genomic library [60]
Cecropin P1 small intestine [38,39,58]
Prophenin-1, 2 leukocytes [60,67,68,133]
Protegrin 1-5 leukocytes [60,97,134]
Horses eNAP-1 neutrophils [135]
eCATH-1, eCATH-2,
eCATH-3
neutrophils [35,50]
Poultry Gal 1/CHP1 heterophils [90,91]
Gal 1a/CHP2 heterophils [91]
Gal 2 heterophils [90,91]
Gal 3 tongue, bursa of Fabricius trachea, skin, oesophagus, air sacs, large intestine, kidney [91,93,136]
THP 1 heterophils [90,137]
THP 2 heterophils [90,137]
THP 3 heterophils [91,93,136,137]
GPV-1 [91,93,136]
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2.2.1. Linear and amphipathic peptides that form a a-
helix
These peptides are 20/40 residues in size, linear and
helical without cysteine residues, and may or may not
have a hinge or ‘kink’ in the middle. If they assume a a-
helical structure, they become amphiphilic, which is
necessary to permeabilize the bacterial cell membrane.
Animal cathelicidins in this group include porcine
cecropin P1; myeloid antimicrobial peptides from pigs
(PMAP), sheep (SMAP) and cattle (BMAP), and the
equine cathelicidins eCATH-1, eCATH-2 and eCATH-3
(Table 1).
Cecropins are basic polypeptides with very potent and
rapid antibacterial activity [37,38]. Cecropin P1, isolated
from porcine small intestine, forms a helical molecule
with a hinge-like sequence of Ser-Glu-Gly. It has a
strong basic N-terminus and a hydrophobic stretch at
the C-terminus and is highly active against Gram-
negative bacteria and some Gram-positive bacteria
[37/39]. The C-terminus carboxyl group is important
for optimal activity against Gram-negative bacteria [38].
P1 is thought to bind to acidic phospholipids in the
bacterial membrane and perturb the lipid packing in the
bilayers [37]. This mechanism explains the specificity of
this peptide for Gram-negative bacteria [37].
A search of porcine bone marrow identified a
transcript with an extended N-terminus similar to the
cathelin proregions of porcine, bovine and rabbit
defence peptides [40]. The C-terminus encoded a novel
peptide termed PMAP23 [40]. This peptide is unique and
has only about 35% homology with CAP18 [41]. The
sequence is highly cationic with five arginines and two
lysines. Synthesized peptide displays remarkable in vitro
antimicrobial activity against Gram-negative bacteria
[41], Gram-positive bacteria [41], yeasts [42] and moulds
[42]. MICs range from 2/16 mM [40,41]. Antibacterial
[41] and antifungal activities [42] appear to be at the
plasma membrane. The peptide can also prevent the
regeneration of fungal cell walls.
SMAP29 and SMAP34 are potent, antimicrobial
peptides of intense interest as potential candidates for
the therapeutic treatment of acute and chronic respira-
tory infections including Pseudomonas aeruginosa asso-
ciated with chronic respiratory inflammation in cystic
fibrosis [11,43/47]. The structure and composition of
SMAP29 (also known as SC5) was first deduced from
sheep myeloid DNA [44,45] and later synthesized to
assess its antimicrobial activity [11,43,46]. SMAP29 has
broad-spectrum antimicrobial activity against Gram-
negative and Gram-positive bacteria and fungi
[11,43,45,46], is active in both low and high ionic
strength conditions [11], and induces significant mor-
phological alterations in bacterial surfaces [46,48]. Its
activity against multiple antibiotic-resistant pathogens
from patients with cystic fibrosis is of particular interest
[47].
SMAP28-NH2 is thought to be the native form of the
peptide [45,46] and synthesized SMAP28-NH2 is anti-
microbial [48]. Only recently, SMAP28-NH2 has been
isolated directly from ovine neutrophils (M. Ferguson,
K. Brogden and B. Tack, unpublished observations).
The antimicrobial activity of cathelicidins is strongly
dependent upon their compositions. In a recent study,
the size and the amino acid composition of SMAP29
was systematically altered to create a family of 23
related peptides [48]. SMAP28, SMAP29, and a deriva-
tive of SMAP29 called ovispirin were all effective
against Gram-negative bacteria (MIC range 0.1/10.0
mg/l), Gram-positive bacteria (MIC range 0.8 to /20.0
mg/l), and Aspergillus fumigatus (MIC 2.5 mg/l). Con-
geners of SMAP29 were not as active as the native
peptide. Large congeners of ovispirin (/16 residues)
were more active than smaller congeners (B/16 residues)
of ovispirin. However, substituting residues in the
peptide or adding an N-terminus amine improved
antimicrobial activity of the small congeners [48].
Ovispirins (OV-1, OV-2 and OV-3) were active against
multiple antibiotic-resistant P. aeruginosa , Burkholderia
cepacia , Achromobacter xylosoxidans and Stenotropho-
monas maltophilia strains isolated from CF patients
(MIC, 0.03/16 mg/l). Cathelicidin-derived peptides
represent a novel class of antimicrobial agents and
warrant further development as prophylactic or ther-
apeutic agents for CF lung disease.
Fig. 1. Transmission electron micrograph of M. haemolytica incu-
bated in zinc saline solution containing 0.5 mM anionic peptide. Note
the distended outer envelope and flocculated intracellular constituents
in affected bacterial cells [22].
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SMAP29 induces extensive ultrastructural damage in
bacterial cells [47,48]. SMAP29 induces bacterial mem-
brane blebs within 1 min, kills P. aeruginosa within 1 h
and causes a dose-dependent, reversible decrease in
transepithelial resistance within 5 h [47]. In transmission
electron microscopy, SMAP29 induces damage charac-
terized by rough surfaces containing extracellular debris
and outer membranous blebs, thickened cell walls and
electron dense cytoplasmic material (Fig. 2). Interest-
ingly, the ultrastructural changes induced by SMAP29
were different from that induced by other peptides like
CAP18 [48]. In addition to severe membrane changes,
SMAP29 rapidly penetrated the outer and inner mem-
branes and entered into the bacterial cytoplasm as early
as time 0 (Fig. 2).
BMAP34 is a peptide of 34 residues deduced from a
bovine cathelicidin gene sequence [49]. BMAP34 is
stored as a proform in the cytoplasmic granules of
bovine neutrophils. CD spectroscopy and secondary
structure analysis indicates that the peptide assumes an
amphipathic alpha-helical conformation. The peptide
exerts a broad-spectrum antimicrobial activity against
both Gram-negative and Gram-positive bacteria and is
not active against eukaryotic cells.
eCATH-1, eCATH-2 and eCATH-3 are cathelicidins
identified in horse bone marrow cells by using RT-PCR
to find the conserved cathelin-like propiece [35]. Se-
quence analysis of amplified products suggested the
presence of three different cathelin sequences [35] and
the deduced C-terminus antimicrobial domains con-
Table 3
Cathelicidins found in domesticated animals
Cathelicidin Sequence References
Cattle
BMAP27 GRFKRFRKKFKKLFKKLSPVIPLLHLG [124]
BMAP28 GGLRSLGRKILRAWKKYGPIIVPIIRIG [124]
BMAP34 GLFRRLRDSIRRGQQKILEKARRIGERIKDIFRG [34]
Bac5 RFRPPIRRPPIRPPFYPPFRPPIRPPIFPPIRPPFRPPLGPFPGRR [54,56]
Bac7 RRIRPRPPRLPRPRPRPLPFPRPGPRPIPRPLPFPRPGPRPIPRPLPFPRPGPRPIPRPL [34,44]
Indolicidin ILPWKWPWWPWRRG [34,69,70]
Dodecapeptide RLCRIVVIRVCR [34,126,127]
Sheep
OaBac5a RFRPXIRRPPIRPPFRPPFRPPVRPPIRPPFRPPFRPPIGPFPGRR [54,128]
OaBac5b RFRPXILRPPIIPPFXPPFXPPVRPPIRPPFRPPFRPPIGPFPGRR [54,128]
OaBac6 RRLRPRHQHFPSERPWPKPLPLPLPRPGPRPWPKPLPLPLPRPGLRPWPKPL [128]
OaBac7.5 RRLRPRRPRLPRPRPRPRPRPRSLPLPRPQPRRIPRPILLPWRPPRPIPRPQPQPIPRWL [44,128]
OaBac11 RRLRPRRPRLPRPRPRPRPRPRSLPLPRPKPRPIPRPLPLPRPRPKPIPRPLPLPRPRPRRIPR-
PLPLPRPRPRPIPRPLPLPQPQPSPIPRPL
[128]
SMAP29 RGLRRLGRKIAHGVKKYGPTVLRIIRIAG [11,43/46]
SMAP34 GLFGRLRDSLQRGGQKILEKAERIWCKIKDIFRG [11,43/46]
Dodeca-peptide RICRIIFLRVCR [44]
Goats
ChBac5 RFRPPIRRPPIRPPFNPPFRPPVRPPFRPPFRPPFRPPIGPFPGRR [54]
Pigs
PMAP23 RIIDLLWRVRRPQKPKFVTVWVR [40,130,131]
PMAP36 GRFRRLRKKTRKRLKKIGKVLKWIPPIVGSIPLGCG [40,41,130]
PMAP37 GLLSRLRDFLSDRGRRLGEKIERIGQKIKDLSEFFQS [41,131]
Cecropin P1 SWLSKTAKKLENSAKKRISEGIAIAIQGGPR [38,39]
PR-39 RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP [38,132]
Protegrin-1 RGGRLCYCRRRFCVCVGR [97]
Protegrin-2 RGGRLCYCRRRFCICV [97]
Protegrin-3 RGGGLCYCRRRFCVCVGR [97]
Protegrin-4 RGGRLCYCRGWICFCVGR [41,134,138]
Protegrin-5 RGGRLCYCRPRFCVCVGR [41,134,138]
Prophenin-1 AFPPPNVPGPRFPPPNFPGPRFPPPNFPGPRFPPPNFPGPRFPPPNFPGPPFPPPIFPGPWFPPPPP-
FRPPPFGPPRFP
[41,68]
Prophenin-2 AFPPPNVPGPRFPPPNVPGPRFPPPNFPGPRFPPPNFPGPRFPPPNFPGPPFPPPIFPGPWFPPPPP-
FRPPPFGPPRFP
[41,68]
Horses
eCATH-1 KRFGRLAKSFLRMRILLPRRKILLAS [35,50]
eCATH-2 KRRHWFPLSFQEFLEQLRRFRDQLPFP [35,50]
eCATH-3 KRFHSVGSLIQRHQQMIRDKSEATRHGIRIITRPKLLLAS [35,50]
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tained 26, 27, and 40 residues (Table 3). Western blot
analysis with antibodies to synthetic eCATH peptides
suggested that eCATH-2 and eCATH-3 are functional
gene products, whereas eCATH-1 is not. These peptides
are thought to be stored as unprocessed forms in equine
neutrophils and when released during inflammation, are
cleaved to yield eCATH-2 and eCATH-3 as well as two
smaller forms of eCATH-3 called eCATH-35-40 and
eCATH-37-40[50]. When synthesized and tested for their
antimicrobial activity, eCATH-1 was the most effective
against Gram-positive and Gram-negative bacteria.
eCATH-2 displayed up to 16-fold higher MICs than
eCATH-1 and eCATH-3. eCATH-35-40 and eCATH-37-
40 were ineffective [50].
2.2.2. Linear peptides, rich in proline
These peptides are 40/80 residues in size, linear
without cysteine residues and may form extended coils.
They have a high proportion of select residues, particu-
larly proline, arginine, glycine or tryptophan. Bactene-
cins (Bac5, Bac7), PR-39, prophenin and indolicidin are
found in this group (Table 1).
Bactenecins are arginine-rich antibacterial peptides
from bovine [51/53], ovine [54] and caprine [54]
neutrophil granules. In cattle, they are containing a
high content of proline (greater than 45%) and arginine
(greater than 23%) residues [52,53]. Bac5 (sometimes
called PR-42) has 42 amino acid residues and a mass of
5000 Da. The peptide has a repeated motif of Arg-Pro-
Table 4
Defensins found in domesticated animals
Defensin Sequence References
Cattle
BNBD-1 DFASCHTNGGICLPNRCPGHMIQIGICFRPRVKCCRSW [77]
BNBD-2 VRNHVTCRINRGFCVPIRCPGRTRQIGTCFGPRIKCCRSW [77]
BNBD-3 pEGVRNHVTCRINRGFCVPIRCPGRTRQIGTCFGPRIKCCRSW [77]
BNBD-4 pERVRNPQSCRWNMGVCIPFLCRVGMRQIGTCFGPRVPCCRR [77]
BNBD-5 pEVVRNPQSCRWNMGVCIPISCPGNMRQIGTCFGPRVPCCR [77]
BNBD-6 pEGVRNHVTCRIYGGFCVPIRCPGRTRQIGTCFGRPVKCCRRW [77]
BNBD-7 pEGVRNFVTCRINRGGFCVPIRCPGHRPQIGTCLGPRIKCCR [77]
BNBD-8 VRNFVTCRINRGFCVPIRCPGHRRQIGTCLGPQIKCCR [77]
BNBD-9 pEGVRNFVTCRINRGFCVPIRCPGHRRQIGTCLGPQIKCCR [77]
BNBD-10 pEGVRSYLSCWGNRGICLLNRCPGRMRQIGTCLAPRVKCCR [77]
BNBD-11 GPLSCRRNGGVCIPIRCPGPMRQIGTCFGRPVKCCRSW [77]
BNBD-12 GPLSCGRNGGVCIPIRCPVPMRQIGTCFGRPVKCCRSW [77]
BNBD-13 SGISGPLSCGRNGGVCIPIRCPVPMRQIGTCFGRPVKCCRSW [77]
TAP NPVSCVRNKGICVPIRCPGSMKQIGTCVGRAVKCCRKK [81,82,84]
LAP QGVRNSQNCRRNKGICVPIRCPGSMRQIGTCLGAQVKCCRRK [83]
EBD GISNPLSCRLNRGICVPIRCPGNLRQIGTCFTPSVKCCRWR [80,123]
Sheep
SBD-1 MRLHHLLLVLFFVVLSAGSGFTQGVRNRLSCHRNKGVCVPSRCPRHMRQIGTCRGPPVKCCRKK (prepropep-
tide sequence)
[86]
SBD-2 MRLHHLLLVLFFVVLSAGSGFTHGVTDSLSCRWKKGICVLTRCPGTMRQIGTCGGPPVKCCRLK (prepropep-
tide sequence)
[86]
Goats
GBD-1 GSGFTQGIRSRRSCHRNKGVCALTRCPRNMRQIGTCFGPPVKCCRKK [139]
GBD-2 GSGFTQGIINHRSCYRNKGVCAPARCPRNMRQIGTCHGPPVKCCRKK [139]
Pigs
PBD-1 KNIGNSVSCLRNKGVCMPGKCAPKMKQIGTCGMPQVKCCKRK [89]
Poultry
Gal 1a/
CHP2
GRKSDCFRKNGFCAFLKCPYLTLISGKCSRFHLCCKRIWG [91,93]
Gal 1/
CHP1
GRKSDCFRKSGFCAFLKCPSLTLISGKCSRFYLCCKRIWG [90,91,93]
Gal 2 LFC KGGSCHFGGCPSHLIKVGSCFGFRS CCKWPWNA [90,91,93]
Gal 3 ATQCRIRGGFCRVGSCRFPHIAIGKCATFISCCGRAYEVDALNSVRTSPWLLAPGNNPH [93]
THP 1 GKREKCLRRNGFCAFLKCPTLSVISGTCSRFQVCCKTLLG [90,93]
THP 2 LFCKRGTCHFGRCPSHLIKVGSCFGFRSCCKWPSDA [90,93]
GPV-1 TPIQCRIRGGFCRFGSCRFPHIAIAKCATFIPCCGSIWG [93]
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Pro triplets alternating with single apolar residues [52].
Bac7 (sometimes called PR-59) has 59 residues and a
mass of 7000 Da. The peptide has three tandem repeats
of a tetradecamer characterized by several Pro-Arg-Pro
triplets spaced by single hydrophobic amino acids [52].
A Bac4 molecule has been found but is thought to be
non-functional, and synthetic Bac4 has no antibacterial
activity [55]. Bac5 and Bac7 are stored as proproteins of
20 and 16 kDa, respectively, in large cytoplasmic
granules present in the neutrophils [56,57] and become
activated by proteases in the azurophils when these
granules fuse with the probactenecin-containing gran-
ules [57]. Both Bac5 and Bac7 have potent antimicrobial
activity in vitro [52,53].
In sheep, there is some heterogeneity in Bac5. Two
proline-rich peptides, OaBac5a and OaBac5b, were
isolated from elastase-treated extracts of sheep leuko-
cytes [54]. OaBac5b was 20/30% as abundant as
OaBac5a, 38 Da smaller and differed from it in 2 of
17 residues [54]. OaBac5a and ChBac5 both exhibited
potent, broad-spectrum antimicrobial activity.
PR-39, originally isolated from the upper part of the
small intestine of the pig, contains high concentrations
of proline (45/49%) and arginine (24/29%) [58,59].
Different forms occur, and PR-39 isolated from porcine
small intestine is slightly different in composition from
that isolated from porcine neutrophils [59]. A variant
form of PR-39, called bPR-39, differs by 3.6%, reflecting
the occasional base pair substitutions scattered through-
out the gene [60]. PR-39 is directly involved in the host
response to infection, and pigs infected with Salmonella
cholerasuis had serum concentrations of PR-39 increase
threefold over prechallenge concentrations of 13.69/1.0
ng/ml [61]. Synthetic and natural forms of the peptide
are active for Gram-negative bacteria only and MICs
range from 1/4 mM [58,62]. However, PR-39 is active
against drug-susceptible as well as multi-drug-resistant
clinical isolates of Mycobacterium tuberculosis [63].
PR-39 does not induce membrane lysis nor kills
bacteria by a non-pore forming mechanism (Table 5).
Instead, it kills bacteria by a mechanism that stops
protein and DNA synthesis after a lag period of about 8
min [58]. Growing bacteria are killed faster than non-
growing bacteria [58]. A charged N-terminus is impor-
tant for peptide activity and the functional antibacterial
domain is in the first 26 amino acid residues of the N-
terminus [59].
PR-39 also affects cell development, differentiation
and metastatic transformation [64]. PR-39 inhibits the
NADPH oxidase activity of neutrophils by blocking
assembly of this enzyme [65]. Again, the presence of a
charged N-terminus is important for these peptide
activities in mammalian systems. For example, PR-39
is a calcium-dependent chemoattractant of neutrophils
but not mononuclear cells, and the chemotactic domain
is in the first 26 amino acid residues [66].
Prophenin is another antimicrobial peptide isolated
from porcine leukocytes [60,67,68]. The name reflects
the abundance of proline (57.1%) and phenylalanine
(19.0%) residues. Two forms exist, prophenin-1 [67] and
prophenin-2 [60,67], that differ in their compositions.
Prophenin-1 is an 8683 Da peptide of 79 residues
encoded on a cathelin-containing precursor [67]. It
contains 42 (53.2%) proline and 15 (19.0%) phenylala-
nine residues. The N-terminal 60 residues consist of
three perfect and three nearly perfect repeats of a
decamer, FPPPNFPGPR. Prophenin-1 is substantially
more active in vitro against E. coli than against Listeria
monocytogenes [67].
Fig. 2. P. aeruginosa incubated with SMAP29. Specific antibody and
Protein A colloidal gold labelling demonstrate the rapid penetration of
the peptide into the bacterial cell. Note the extensive outer membrane
material that has been ‘scrubbed’ from the bacterial cell surface [48].
Table 5
Mechanisms of antimicrobial activity of peptides from domesticated
animals
Antimicrobial activity Peptide References
Ion channel formation cecropins [58,140]
defensins [141]
Inhibition of DNA and protein synthesis PR-39 [58]
Effect on transport and energy metabolism
in cytoplasmic membrane
Bac5, Bac7 [51]
Flocculation of intracellular contents anionic pep-
tides
[22]
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Indolicidin is a tryptophan-rich, 13 amino acid,
antimicrobial peptide isolated from the large cytoplas-
mic granules of bovine neutrophils [69]. The deduced
form from bovine marrow cells is a 14 amino acid
peptide [70]. The glycine found at the C-terminus end of
the peptide is not found in the purified peptide [69],
suggesting that the deduced sequence is very likely
involved in post-translational peptide amidation. The
peptide contains five tryptophans, three prolines, three
basic residues, and no acidic residues [69,71]. The MIC
is less than 10 mg/l for both Gram-negative and Gram-
positive bacteria [69]. Indolicidin is highly membrane-
active and is believed to disrupt cell membranes by
binding to phospholipids [71].
2.2.3. Cysteine-stabilized peptides with a b-sheet
structure
These peptides are 16/40 residues in size, contain
cysteines, have two or more disulphide bonds and form
a stabilized b-sheet structure. This group contains the
a-, b-defensins and protegrins (Tables 1 and 4).
a-Defensins, often called classical defensins, have 29/
35 residues and are found in the azurophil granules of
neutrophils of humans and many smaller mammalian
species such as guinea pigs, rabbits, rats and mice [72].
These peptides are stored in high concentrations in
granules, specialized organelles of phagocytes (granulo-
cytes and some macrophages) and Paneth cells [72].
They are active at 1/100 mg/l against Gram-positive
bacteria, Gram-negative bacteria, mycobacteria, fungi
and enveloped viruses [72/75].
b-Defensins have 38/42 residues and are arginine-rich
with broad antimicrobial, antiviral and cytotoxic activ-
ity [76]. In cattle, thirteen b-defensins are found in the
granule-rich cytoplasmic fraction of purified blood
neutrophils and are called bovine neutrophil beta
defensins or BNBD [77]. These 13 homologous peptides
are highly cationic and share conserved consensus
sequence with epithelial antimicrobial peptides [77]. All
were active against S. aureus and E. coli [77].
BNBD-4, BNBD-12 and BNBD-13 have been studied
in detail [78,79]. Early work with BNBD-12 established
that disulphide motifs of BNBD differed from that of
classical defensins, showing that b- and a-defensins have
differently folded chains, though they share several
functional properties [79]. The 41 residue of BNBD-4
was found to originate from a 63 residue prepropeptide,
whereas the 38 and 42 residues BNBD-12 and BNBD-13
originated from a common 60 residue prepropeptide
[78]. Two-exon genes that are closely related to bovine
epithelial defensin genes encode the peptides. BNBD-4
and BNBD-12/13 mRNAs are abundant in bone mar-
row but are expressed differentially in certain non-
myeloid tissues [78]. BNBD-12 is in dense granules
and is the predominant organelle form in myeloid cells.
In bovine alveolar macrophages, BNBD-4, BNBD-5,
TAP, and EBD are constitutively expressed [80]. Ex-
posure to LPS did not induce BNBD expression in
bovine alveolar macrophages but did induce expression
of tumour necrosis factor alpha.
Two epithelial b-defensins, tracheal antimicrobial
peptide (TAP), and lingual antimicrobial peptide
(LAP) are found in columnar cells of the pseudostrati-
fied epithelium throughout the conducting airway and
tongue [81/84]. TAP is expressed in nasal, tracheal and
bronchiolar tissues [84]. However, mRNA encoding
TAP is more abundant in the respiratory mucosa than
in whole lung tissue [82] and is not expressed in alveolar
sections or submucosal glands [84]. TAP is not expressed
prenatally in foetal calves [84]. LAP was isolated from
bovine tongue and has a broad-spectrum of antibacter-
ial and antifungal activities [83].
TAP gene expression dramatically increases in pri-
mary cultures of bovine airway epithelial cells incubated
with LPS [84,85]. At 10 ng/ml, there was a 5- to 10-fold
increase in TAP expression [85]. Similarly, LAP mRNA
was markedly increased in the epithelium surrounding
naturally occurring tongue lesions. This increase coin-
cided with the cellular hallmarks of acute and chronic
inflammation in the underlying lamina propria, support-
ing its role as an integral component of the inflamma-
tory response.
In sheep, SBD-1 and SBD-2 are expressed throughout
the gastrointestinal tract [86]. SBD-1 mRNA is the most
prevalent from the tongue to colon with the exception of
the distal ileum, where SBD-2 mRNA predominates.
SBD expression also varies significantly between ani-
mals and is developmentally regulated both pre- and
post-natally. High resolution chromosomal fluorescence
in situ hybridization (FISH) and R-banding localized
the b-defensin cluster to chromosome band 24q13 [87].
In goats, two b-defensin precursors, preproGBD-1
and preproGBD-2, are also found [88]. They are
identical in 96.8% of their bases and 88.2% (60 of 68)
of their amino acids. However, preproGBD-1 is ex-
pressed principally in the tongue and respiratory tract,
whereas preproGBD-2 is expressed throughout the
intestine.
In pigs, PBD-1 is expressed in the cornified tip of the
filiform papillae of the dorsal tongue and in the super-
filial squamous cell layers of the buccal mucosa [89]. The
cDNA sequence of PBD-1 encodes a 64 amino acid
prepro-peptide, which contains the 42 residue natural
form [89]. mRNA was detected throughout the respira-
tory and digestive tracts and also in thymus, spleen,
lymph node, brain, liver, kidney, urinary bladder, testis,
skin, heart, muscle, bone marrow, peripheral blood
neutrophils, alveolar macrophages and umbilical cord.
The peptide is antimicrobial at 40 mg/l, and activity is
synergistic with other neutrophil-derived antimicrobial
peptides, such as PG-3 and PR-39 [89].
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In poultry, four chicken b-defensins (Gal 1/CHP1,
Gal 1a/CHP2, Gal 2, and Gal 3) and four turkey b-
defensins (THP 1, THP 2, THP 3 and GPV-1) have been
reported [90/93]. The peptides contain 36/39 amino
acid residues and are relatively cationic due to their
numerous lysine and arginine residues. Three intramo-
lecular cystine disulphide bonds are present [91]. These
peptides were /90% effective at 2/16 mg/l concentra-
tions against E. coli and L. monocytogenes [91,92]. In
normal chickens, the expression of Gal-3 is especially
prominent in the tongue, bursa of Fabricius and trachea
[93] but also occurs in the skin, oesophagus, air sacs,
large intestine and kidney. Tracheal expression of Gal 3
increased significantly after experimental infection of
chickens with Haemophilus paragallinarum , whereas its
expression in the tongue, oesophagus, and bursa of
Fabricius was unaffected. The precursor of Gal 3
contains a long C-terminal extension not present in the
prepropeptide. By comparing the cDNA sequences of
Gal 3 and GPV-1, it appears that a 2-nucleotide
insertion into the Gal 3 gene has induced a frameshift
that reads through the original stop codon and allows
the chicken propeptide to lengthen.
Another defensin-like molecule was recently isolated
from the granules of neutrophils and monocytes of
rhesus macaques [94]. This peptide is an 18-residue
macrocyclic, tridisulphide antibiotic peptide termed
rhesus theta defensin-1 (RTD-1). The peptide backbone
is cyclized through peptide bonds with an extended beta-
hairpin structure with turns at one or both ends [95]. In
contrast to numerous other antimicrobial peptides,
RTD-1 does not display any amphiphilic character,
even though surface models of RTD-1 exhibit a certain
clustering of positive charges [95]. It is microbicidal for
bacteria and fungi at low micromolar concentrations.
Antibacterial activity of the cyclic peptide was threefold
greater than that of an open-chain analog, and the cyclic
conformation was required for antimicrobial activity in
the presence of 150 mM sodium chloride. Biosynthesis
of RTD-1 involves the head- to-tail ligation of two a-
defensin-related nonapeptides, requiring the formation
of two new peptide bonds.
Animal protegrins consist of five cysteine-rich natu-
rally occurring cationic antimicrobial peptides [96]. In
porcine leukocytes, protegrins contain 16 residues with
four cysteines stabilized by two intramolecular disul-
phide bonds [97]. Although the primary amino acid
sequences of the protegrins show minimal homology to
the b-defensins, the first 3-cysteine residues are spaced
identically to those of a-defensins [97]. Two antiparallel
b-sheets are linked by a b-hairpin turn [96]. In artificial
membranes, they form dimeric structures, which aggre-
gate forming a larger pore [96]. Protegrins are stored as
inactive proforms in neutrophil granules and are acti-
vated extracellularly by neutrophil elastase [98]. They
have potent activity against Gram-negative bacteria,
Gram-positive bacteria and fungi [97].
2.3. Peptides as fragments of larger proteins
One final area worth mentioning includes the isola-
tion of antimicrobial domains often residing in larger
antimicrobial proteins. These domains are thought to be
natural enzymatic digestion products of larger mole-
cules, perhaps consumed and degraded in the intestinal
tract. These include lysosome residues 98 through 112
[99], a lactoferrin fragment called lactoferricin [100/104]
and hen ovotransferrin residues located within the 109/
200 sequence of the N-terminus [105]. These studies
suggest that ingested bovine lactoferrin is partially
degraded by gastric contents to antimicrobial fragments
containing the lactoferricin region [103]. These peptides
then exhibit broad-spectrum antimicrobial activity in
the gastrointestinal tract [100,101,104].
3. Therapeutic potential
The highly active nature of antimicrobial peptides in
vitro suggests these peptides might be effective in
treating bacterial infections in vivo. To test this, a
model of acute pneumonia in lambs was established
using the ovine respiratory pathogen M. haemolytica. In
one study, a single bronchial instillation of 0.5 mg
SMAP29 reduced the concentration of bacteria in both
the bronchoalveolar lavage fluid and consolidated
pulmonary tissues [43](Fig. 3). In another study, a single
bronchial instillation of 0.5 mg anionic peptide also
reduced pulmonary inflammation and the concentration
of M. haemolytica in infected lung tissue [106]. The in
vitro and in vivo effectiveness of SMAP29 and anionic
peptides suggests that they may have applications in the
treatment or prevention of pulmonary infections. How-
ever, further studies are needed to confirm these findings
and also to determine the optimal doses and intervals of
antimicrobial peptide therapy.
4. Future areas of research
The field of antimicrobial peptides in animals is
expanding and substantial advances are expected. First,
new genes encoding antimicrobial peptides will likely be
found in sequenced animal genomes. For example, four
b-defensins were discovered in human tissues, urine, and
secretions [107/112]. Recently, Schutte et al., using a
genomics approach, identified 28 new human b-defensin
and 43 new mouse b-defensin genes in five syntenic
chromosomal regions. Within each syntenic cluster, the
gene sequences and organization were similar, suggest-
ing each cluster pair arose from a common ancestor and
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was retained because of conserved functions [113]. The
discovery of these novel b-defensin genes exemplifies
how sequencing of animal genomes may also identify
new antimicrobial gene products.
Second, conventional animals or transgenic animals
will be likely be used as a source of antimicrobial
peptides for use in the food and health industry. Bovine
lactoferrin, a byproduct from cheese whey or skim milk,
is commercially available as a health food in Japan [114]
and has been used in a wide variety of products since it
was first added to infant formula in 1986 [115].
Similarly, recombinant human lactoferrin (rhLF), was
found in transgenic cow’s milk at gram per litre
concentrations [116]. Natural hLF from human milk
and rhLF had identical iron-binding and iron-release
properties and were equally effective in three different in
vivo infection models employing immunocompetent and
leukocytopenic mice [116]. Lactoferrins have little
toxicity and are very safe, especially when administered
orally. The oral toxicity of purified lactoferrin is
extremely low and 2000 mg/kg/day did not cause any
adverse effects in rats of both sexes [115,117]. Similarly,
434 mg/kg lactoferrin was not toxic for mice [118]. Based
on these results, lactoferrin was considered to be a
highly safe food additive in supplemented infant for-
mula, milk, skim milk, yoghurt, chewing gum, nutri-
tional supplements, skin care cosmetics, therapeutic diet
for relief of inflammation in dogs and cats and in
aquaculture feed [115].
Third, antimicrobial peptides have immunoenhancing
activities. For example, human neutrophil peptides
(HNP) can induce adaptive immune responses to foreign
antigens. Lillard et al. showed that a mixture of native
HNPs (containing HNP-1, HNP-2 and HNP-3) induced
adaptive host immunity to ovalbumin in mice [119].
Intranasal delivery of HNPs plus ovalbumin enhanced
ovalbumin-specific IgG, but not IgA, antibody re-
sponses. Ovalbumin specific T cells showed marked
increases in ovalbumin-specific proliferative responses
and produced greater amounts of CD4 Th1 and Th2
cytokines (interferon-g, IL-5, IL-6 and IL-10). Similar
work by Brogden et al. showed that HNPs and HBDs
could also induce adaptive immune responses to oval-
bumin [120]. Different antibody isotype and cytokine
profiles, unique to the individual HNP or HBD used,
were seen. Such immunoenhancing properties could be
Fig. 3. Lungs of lambs infected with M. haemolytica [43]. The anterior part of the right cranial lobe (A) of infected lambs consisted of areas of
consolidation with necrosis and haemorrhage. Lumens contained large numbers of neutrophils, cell debris and proteinaceous exudate (B). The lesion
is significantly reduced 24 h after a single treatment with SMAP29 (C). The bronchiolar walls contained moderate numbers of lymphocytes, but there
was no acute inflammatory response (D).
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used to augment or direct favourable immune responses
to co-administered antigens in vaccines for prophylactic
prevention of disease [120].
5. Summary
In this review, we presented an updated list of
antimicrobial peptides found in domesticated animals
including their sites of production, antimicrobial activity
and their potential use for therapeutic treatment of
infectious disease. These antimicrobial peptides are
conserved in their structure, function and mechanisms
of action, and thus it might be possible to use them to
prevent or treat microbial infections. First, these pep-
tides are generally broad-spectrum for Gram-positive
bacteria, Gram-negative bacteria and fungi. Synthetic
antimicrobial peptides or their congeners might be used
directly as antimicrobial agents to treat infections.
Preliminary studies presented here suggest that this
may be possible. Second, as we begin to identify the
mechanisms to initiate synthesis and release of anti-
microbial peptides, it may also be possible to find ways
to trigger their production in animals at times when they
are most susceptible to microbial infection. Such pro-
phylactic treatment may help animals through stressful
periods (e.g. exposure to inclement weather, poor
ventilation with high levels of moisture and barnyard
gases, handling and transport, castration and docking,
weaning and change in feed, high loads of parasites and
mixing of animals from different sources). Third, it may
be possible to use virus-mediated gene transfer to
express antimicrobial peptides in pulmonary epithelia
before or during infectious disease outbreaks. This
would be particularly applicable in situations involving
respiratory infections. Finally, it is possible that anti-
microbial peptides could be used as mucosal adjuvants
to augment or direct favourable immune responses to
co-administered antigens in vaccines for prophylactic
prevention of disease [120].
References
[1] Wegener HC, Aarestrup FM, Jensen LB, Hammerum AM,
Bager F. Use of antimicrobial growth promoters in food animals
and Enterococcus faecium resistance to therapeutic antimicrobial
drugs in Europe. Emerg Infect Dis 1999;5:329/35.
[2] Witte W. Medical consequences of antibiotic use in agriculture.
Science 1998;279:996/7.
[3] Witte W, Tschape H, Klare I, Werner G. Antibiotics in animal
feed. Acta Vet Scand 2000;93(Suppl):37/45.
[4] Diekema DJ, Brueggemann AB, Doern GV. Antimicrobial-drug
use and changes in resistance in Streptococcus pneumoniae .
Emerg Infect Dis 2000;6:552/6.
[5] Gaynes R, Monnet D. The contribution of antibiotic use on the
frequency of antibiotic resistance in hospitals. Ciba Found Symp
1997;207:47/56.
[6] Gaynes R. The impact of antimicrobial use on the emergence of
antimicrobial-resistant bacteria in hospitals. Infect Dis Clin
North Am 1997;11:757/65.
[7] Marwick C. Animal feed antibiotic use raises drug resistance
fear. J Am Med Assoc 1999;282:120/2.
[8] Gorbach SL. Antimicrobial use in animal feed*/time to stop. N
Engl J Med 2001;345:1202/3.
[9] Arthur M, Reynolds P, Courvalin P. Glycopeptide resistance in
enterococci. Trends Microbiol 1996;4:401/7.
[10] Jacoby GA. Antimicrobial-resistant pathogens in the 1990s.
Annu Rev Med 1996;47:169/79.
[11] Travis SM, Anderson NN, Forsyth WR, et al. Bactericidal
activity of mammalian cathelicidin-derived peptides. Infect
Immun 2000;68:2748/55.
[12] Hirata M, Shimomura Y, Yoshida M, et al. Characterization of
a rabbit cationic protein (CAP18) with lipopolysaccharide-
inhibitory activity. Infect Immun 1994;62:1421/6.
[13] Zanetti M, Gennaro R, Romeo D. Cathelicidins: a novel protein
family with a common proregion and a variabe C-terminal
antimicrobial domain. FEBS Lett 1995;374:1/5.
[14] Gallo RL, Kim KJ, Bernfield M, et al. Identification of
CRAMP, a cathelin-related antimicrobial peptide expressed in
the embryonic and adult mouse. J Biol Chem 1997;272:13088/
93.
[15] Sawa T, Kurahashi K, Ohara M, et al. Evaluation of anti-
microbial and lipopolysaccharide-neutralizing effects of a syn-
thetic CAP18 fragment against Pseudomonas aeruginosa in a
mouse model. Antimicrob Agents Chemother 1998;42:3269/75.
[16] Boman HG. Peptide antibiotics and their role in innate
immunity. Annu Rev Immunol 1995;13:61/92.
[17] Nissen-Meyer J, Nes IF. Ribosomally synthesized antimicrobial
peptides: their function, structure, biogenesis, and mechanism of
action. Arch Microbiol 1997;167:67/77.
[18] Lehrer RI, Ganz T. Antimicrobial peptides in mammalian and
insect host defence. Curr Opin Immunol 1999;11:23/7.
[19] Hancock REW. Peptide antibiotics. Lancet 1997;349:418/22.
[20] Nicolas P, Mor A. Peptides as weapons against microorganisms
in the chemical defense system of vertebrates. Annu Rev
Microbiol 1995;49:277/304.
[21] Brogden KA. Ovine pulmonary surfactant induces killing of
Pasteurella haemolytica , Escherichia coli , and Klebsiella pneu-
moniae by normal serum. Infect Immun 1992;60:5182/9.
[22] Brogden KA, De Lucca AJ, Bland J, Elliott S. Isolation of an
ovine pulmonary surfactant-associated anionic peptide bacter-
icidal for Pasteurella haemolytica . Proc Natl Acad Sci USA
1996;93:412/6.
[23] de Haen C, Neurath H, Teller DC. The phylogeny of trypsin-
related serine proteases and their zymogens. New methods for
the investigation of distant evolutionary relationships. J Mol
Biol 1975;92:225/59.
[24] Brogden KA, Ackermann M, Huttner KM. Small, anionic, and
charge-neutralizing propeptide fragments of zymogens are anti-
microbial. Antimicrob Agents Chem 1997;41:1615/7.
[25] Caverly JM, Radi ZA, Andreasen CB, Dixon RA, Brogden KA,
Ackermann MR. Comparison of bronchoalveolar lavage fluid
obtained from Mannheimia haemolytica -inoculated calves with
and without prior treatment with the selectin inhibitor TBC1269.
Am J Vet Res 2001;62:665/72.
[26] Brogden KA, Ackermann M, Huttner KM. Detection of anionic
antimicrobial peptides in ovine bronchoalveolar lavage fluid and
respiratory epithelium. Infect Immun 1998;66:5948/54.
[27] Schlievert P, Johnson W, Galask RP. Bacterial growth inhibition
by amniotic fluid. VI. Evidence for a zinc-peptide antibacterial
system. Am J Obstet Gynecol 1976;125:906/10.
[28] Ellison RT, III, Boose D, LaForce FM. Isolation of an
antibacterial peptide from human lung lavage fluid. J Infect
Dis 1985;151:1123/9.
K.A. Brogden et al. / International Journal of Antimicrobial Agents 22 (2003) 465/478 475
[29] LaForce FM, Boose DS. Effect of zinc and phosphate on an
antibacterial peptide isolated from lung lavage. Infect Immun
1984;45:692/6.
[30] Bottari E. Zinc(II) complexes with aspartate and glutamate. J
Coord Chem 1990;21:215/24.
[31] Littauer UZ, Sela M. An ultracentrifugal study of the efficiency
of some macromolecular inhibitors of ribonuclease. Biochim
Biophys Acta 1962;61:609/11.
[32] Sela M. Inhibition of ribonuclease by copolymers of glutamic
acid and aromatic amino acids. J Biol Chem 1962;237:418/21.
[33] Vandendriessche L. Inhibitors of ribonuclease activity. Arch
Biochem Biophys 1956;65:347/53.
[34] Scocchi M, Wang SL, Zanetti M. Structural organization of the
bovine cathelicidin gene family and identification of a novel
member. FEBS Lett 1997;417:311/5.
[35] Scocchi M, Bontempo D, Boscolo S, Tomasinsig L, Giulotto E,
Zanetti M. Novel cathelicidins in horse leukocytes. FEBS Lett
1999;457:459/64.
[36] Gennaro R, Zanetti M. Structural features and biological
activities of the cathelicidin- derived antimicrobial peptides.
Biopolymers 2000;55:31/49.
[37] Gazit E, Boman A, Boman HG, Shai Y. Interaction of the
mammalian antibacterial peptide cecropin P1 with phospholipid
vesicles. Biochemistry 1995;34:11479/88.
[38] Vunnam S, Juvvadi P, Merrifield RB. Synthesis and antibacterial
action of cecropin and proline-arginine-rich peptides from pig
intestine. J Pept Res 1997;49:59/66.
[39] Lee J-Y, Boman A, Chuanxin S, et al. Antibacterial peptides
from pig intestine: Isolation of a mammalian cecropin. Proc Natl
Acad Sci USA 1989;86:9159/62.
[40] Zanetti M, Storici P, Tossi A, Scocchi M, Gennaro R. Molecular
cloning and chemical synthesis of a novel antibacterial peptide
derived from pig myeloid cells. J Biol Chem 1994;269:7855/8.
[41] Zhang G, Ross CR, Blecha F. Porcine antimicrobial peptides:
new prospects for ancient molecules of host defense. Vet Res
2000;31:277/96.
[42] Lee DG, Kim DH, Park Y, et al. Fungicidal effect of
antimicrobial peptide, PMAP-23, isolated from porcine myeloid
against Candida albicans . Biochem Biophys Res Commun
2001;282:570/4.
[43] Brogden KA, Kalfa VC, Ackermann MR, Palmquist DE,
McCray PB, Jr., Tack BF. The ovine cathelicidin SMAP29 kills
ovine respiratory pathogens in vitro and in an ovine model of
pulmonary infection. Antimicrob Agents Chemother
2001;45:331/4.
[44] Bagella L, Scocchi M, Zanetti M. cDNA sequences of three
sheep myeloid cathelicidins. FEBS Lett 1995;376:225/8.
[45] Mahoney MM, Lee AY, Brezinski-Caliguri DJ, Huttner KM.
Molecular analysis of the sheep cathelin family reveals a novel
antimicrobial peptide. FEBS Lett 1995;377:519/22.
[46] Skerlavaj B, Benincasa M, Risso A, Zanetti M, Gennaro R.
SMAP-29: a potent antibacterial and antifungal peptide from
sheep leukocytes. FEBS Lett 1999;463:58/62.
[47] Saiman L, Tabibi S, Starner TD, et al. Cathelicidin peptides
inhibit multiply antibiotic-resistant pathogens from patients with
cystic fibrosis. Antimicrob Agents Chemother 2001;45:2838/44.
[48] Kalfa VC, Jia HP, Kunkle RA, McCray PB, Jr., Tack BF,
Brogden KA. Congeners of SMAP29 kill ovine pathogens and
induce ultrastructural damage in bacterial cells. Antimicrob
Agents Chemother 2001;45:3256/61.
[49] Gennaro R, Scocchi M, Merluzzi L, Zanetti M. Biological
characterization of a novel mammalian antimicrobial peptide.
Biochim Biophys Acta 1998;1425:361/8.
[50] Skerlavaj B, Scocchi M, Gennaro R, Risso A, Zanetti M.
Structural and functional analysis of horse cathelicidin peptides.
Antimicrob Agents Chemother 2001;45:715/22.
[51] Skerlavaj B, Romeo D, Gennaro R. Rapid membrane permea-
bilization and inhibition of vital functions of Gram-negative
bacteria by bactenecins. Infect Immun 1990;58:3724/30.
[52] Frank RW, Gennaro R, Schneider K, Przybylski M, Romeo D.
Amino acid sequences of two proline-rich bactenecins. Anti-
microbial peptides of bovine neutrophils. J Biol Chem
1990;265:18871/4.
[53] Gennaro R, Skerlavaj B, Romeo D. Purification, composition,
and activity of two bactenecins, antibacterial peptides of bovine
neutrophils. Infect Immun 1989;57:3142/6.
[54] Shamova O, Brogden KA, Zhao C, Nguyen T, Kokryakov VN,
Lehrer RI. Purification and properties of proline-rich antimicro-
bial peptides from sheep and goat leukocytes. Infect Immun
1999;67:4106/11.
[55] Scocchi M, Wang SL, Gennaro R, Zanetti M. Cloning and
analysis of a transcript derived from two contiguous genes of the
cathelicidin family. Biochim Biophys Acta Gene Struct Expr
1998;1398:393/6.
[56] Zanetti M, Del Sal G, Storici P, Schneider C, Romeo D. The
cDNA of the neutrophil antibiotic Bac5 predicts a pro-sequence
homologous to a cysteine proteinase inhibitor that is common to
other neutrophil antibiotics. J Biol Chem 1993;268:522/6.
[57] Zanetti M, Litteri L, Gennaro R, Horstmann H, Romeo D.
Bactenecins, defense polypeptides of bovine neutrophils, are
generated from precursor molecules stored in the large granules.
J Cell Biol 1990;111:1363/71.
[58] Boman HG, Agerberth B, Boman A. Mechanisms of action on
Escherichia coli of cecropin P1 and PR-39, two antibacterial
peptides from pig intestine. Infect Immun 1993;61:2978/84.
[59] Shi J, Ross CR, Chengappa MM, Sylte MJ, McVey DS, Blecha
F. Antibacterial activity of a synthetic peptide (PR-26) derived
from PR-39, a proline-arginine-rich neutrophil antimicrobial
peptide. Antimicrob Agents Chem 1996;40:115/21.
[60] Zhao C, Ganz T, Lehrer RI. Structures of genes for two cathelin-
associated antimicrobial peptides: prophenin-2 and PR-39.
FEBS Lett 1995;376:130/4.
[61] Zhang G, Ross CR, Dritz SS, Nietfeld JC, Blecha F. Salmonella
infection increases porcine antibacterial peptide concentrations
in serum. Clin Diagn Lab Immunol 1997;4:774/7.
[62] Shi J, Ross CR, Chengappa MM, Blecha F. Identification of a
proline-argining-rich antibacterial peptide from neutrophils that
is analogous to PR-39, and antibacterial peptide from the small
intestine. J Leukoc Biol 1994;56:807/11.
[63] Linde CM, Hoffner SE, Refai E, Andersson M. In vitro activity
of PR-39, a proline-arginine-rich peptide, against susceptible and
multi-drug-resistant Mycobacterium tuberculosis . J Antimicrob
Chemother 2001;47:575/80.
[64] Chan YR, Zanetti M, Gennaro R, Gallo RL. Anti-microbial
activity and cell binding are controlled by sequence determinants
in the anti-microbial peptide PR-39. J Invest Dermatol
2001;116:230/5.
[65] Ikeda Y, Young LH, Scalia R, Ross CR, Lefer AM. PR-39, a
proline/arginine-rich antimicrobial peptide, exerts cardioprotec-
tive effects in myocardial ischemia-reperfusion. Cardiovasc Res
2001;49:69/77.
[66] Huang HJ, Ross CR, Blecha F. Chemoattractant properties of
PR-39, a neutrophil antibacterial peptide. J Leukoc Biol
1997;61:624/9.
[67] Harwig SS, Kokryakov VN, Swiderek KM, Aleshina GM, Zhao
C, Lehrer RI. Prophenin-1, an exceptionally proline-rich anti-
microbial peptide from porcine leukocytes. FEBS Lett
1995;362:65/9.
[68] Strukelj B, Pungercar J, Kopitar G, et al. Molecular cloning and
identification of a novel porcine cathelin-like antibacterial
peptide precursor. Biol Chem Hoppe-Seyler 1995;376:507/10.
K.A. Brogden et al. / International Journal of Antimicrobial Agents 22 (2003) 465/478476
[69] Selsted ME, Novotny MJ, Morris WL, Tang YQ, Smith W,
Cullor JS. Indolicidin, a novel bactericidal tridecapeptide amide
from neutrophils. J Biol Chem 1992;267:4292/5.
[70] Del Sal G, Storici P, Schneider C, Romeo D, Zanetti M. cDNA
cloning of the neutrophil bactericidal peptide indolicidin.
Biochem Biophys Res Commun 1992;187:467/72.
[71] Ladokhin AS, Selsted ME, White SH. Bilayer interactions of
indolicidin, a small antimicrobial peptide rich in tryptophan,
proline, and basic amino acids. Biophys J 1997;72:794/805.
[72] Ganz T, Lehrer RI. Defensins. Pharmac Ther 1995;66:191/205.
[73] Lehrer RI, Selsted ME, Szklarek D, Fleischmann J. Antibacter-
ial activity of microbicidal cationic proteins 1 and 2, matural
peptide antibiotics of rabbit lung macrophages. Infect Immun
1983;42:10/4.
[74] Lehrer RI, Ganz T, Szklarek D, Selsted ME. Modulation of the
in vitro candidacidal activity of human neutrophil defensins by
target cell metabolism and divalent cations. J Clin Invest
1988;81:1829/35.
[75] Lehrer RI, Daher K, Ganz T, Selsted ME. Direct inactivation of
viruses by MCP-1 and MCP-2, natural peptide antibiotics from
rabbit leukocytes. J Virol 1985;54:467/72.
[76] Ganz T, Selsted ME, Lehrer RI. Defensins. Eur J Haematol
1990;44:1/8.
[77] Selsted ME, Tang Y-Q, Morris WL, et al. Purification, primary
structures, and antibacterial activities of b-defensins, a new
family of antimicrobial peptides from bovine neutrophils. Biol
Chem 1993;268:6641/8.
[78] Yount NY, Yuan J, Tarver A, et al. Cloning and expression of
bovine neutrophil beta-defensins. Biosynthetic profile during
neutrophilic maturation and localization of mature peptide to
novel cytoplasmic dense granules. J Biol Chem 1999;274:26249/
58.
[79] Tang YQ, Selsted ME. Characterization of the disulfide motif in
BNBD-12, an antimicrobial beta-defensin peptide from bovine
neutrophils. J Biol Chem 1993;268:6649/53.
[80] Ryan LK, Rhodes J, Bhat M, Diamond G. Expression of beta-
defensin genes in bovine alveolar macrophages. Infect Immun
1998;66:878/81.
[81] Diamond G, Zasloff M, Eck H, Brasseur M, Maloy WL, Bevins
CL. Tracheal antimicrobial peptide, a cysteine-rich peptide from
mammalian tracheal mucosa: peptide isolation and cloning of a
cDNA. Proc Natl Acad Sci USA 1991;88:3952/6.
[82] Diamond G, Zasloff M, Eck H, Brasseur M, Maloy W, Bevins
C. A novel antimicrobial peptide from mammalian tracheal
mucosa. Chest 1992;101:47S.
[83] Schonwetter BS, Stolzenberg ED, Zasloff MA. Epithelial anti-
biotics induced at sites of inflammation. Science 1995;267:1645/
8.
[84] Diamond G, Jones DE, Bevins CL. Airway epithelial cells are
the site of expression of a mammalian antimicrobial peptide
gene. Proc Natl Acad Sci USA 1993;90:4596/600.
[85] Diamond G, Bevins C. Endotoxin upregulates expression of an
antimicrobial peptide gene in mammalian airway epithelial cells.
Chest 1994;105:51S/2S.
[86] Huttner KM. Antimicrobial peptide expression is developmen-
tally regulated in the ovine gastrointestinal tract. Am Soc Nutr
Sci 1998:297S/9S.
[87] Iannuzzi L, Gallagher DS, Di Meo GP, Diamond G, Bevins CL,
Womack JE. High-resolution FISH mapping of b-defensin genes
to river buffalo and sheep chromosomes suggests a chromosome
discrepancy in cattle standard karyotypes. Cytogenet Cell Genet
1996;75:10/3.
[88] Zhao C, Nguyen T, Liu L, Shamova O, Brogden K, Lehrer RI.
Differential expression of caprine b-defensins in digestive and
respiratory tissues. Infect Immun 1999;67:6221/4.
[89] Shi J, Zhang G, Wu H, Ross C, Blecha F, Ganz T. Porcine
epithelial b-defensin 1 is expressed in the dorsal tongue at
antimicrobial concentrations. Infect Immun 1999;67:3121/7.
[90] Brockus CW, Jackwood MW, Harmon BG. Characterization of
beta-defensin prepropeptide mRNA from chicken and turkey
bone marrow. Anim Genet 1998;29:283/9.
[91] Harwig SS, Swiderek KM, Kokryakov VN, et al. Gallinacins:
cysteine-rich antimicrobial peptides of chicken leukocytes. FEBS
Lett 1994;342:281/5.
[92] Evans EW, Beach FG, Moore KM, Jackwood MW, Glisson JR,
Harmon BG. Antimicrobial activity of chicken and turkey
heterophil peptides CHP1, CHP2, THP1, and THP3. Vet
Microbiol 1995;47:295/303.
[93] Zhao C, Nguyen T, Liu L, Sacco RE, Brogden KA, Lehrer RI.
Gallinacin-3, an inducible epithelial beta-defensin in the chicken.
Infect Immun 2001;69:2684/91.
[94] Tang YQ, Yuan J, Osapay G, et al. A cyclic antimicrobial
peptide produced in primate leukocytes by the ligation of two
truncated alpha-defensins. Science 1999;286:498/502.
[95] Trabi M, Schirra HJ, Craik DJ. Three-dimensional structure of
RTD-1, a cyclic antimicrobial defensin from rhesus macaque
leukocytes. Biochemistry 2001;40:4211/21.
[96] Roumestand C, Louis V, Aumelas A, Grassy G, Calas B,
Chavanieu A. Oligomerization of protegrin-1 in the presence of
DPC micelles. A proton high-resolution NMR study. FEBS Lett
1998;421:263/7.
[97] Kokryakov VN, Harwig SS, Panyutich EA, et al. Protegrins:
leukocyte antimicrobial peptides that combine features of
corticostatic defensins and tachyplesins. FEBS Lett
1993;327:231/6.
[98] Shi JS, Ganz T. The role of protegrins and other elastase-
activated polypeptides in the bactericidal properties of porcine
inflammatory fluids. Infect Immun 1998;66:3611/7.
[99] Pellegrini A, Thomas U, Bramaz N, Klauser S, Hunziker P, von
Fellenberg R. Identification and isolation of a bactericidal
domain in chicken egg white lysozyme. J Appl Microbiol
1997;82:372/8.
[100] Dionysius DA, Milne JM. Antibacterial peptides of bovine
lactoferrin: purification and characterization. J Dairy Sci
1997;80:667/74.
[101] Haug BE, Skar ML, Svendsen JS. Bulky aromatic amino acids
increase the antibacterial activity of 15-residue bovine lactofer-
ricin derivatives. J Pept Sci 2001;7:425/32.
[102] Kuwata H, Yip TT, Yip CL, Tomita M, Hutchens TW.
Bactericidal domain of lactoferrin: detection, quantitation, and
characterization of lactoferricin in serum by SELDI affinity mass
spectrometry. Biochem Biophys Res Commun 1998;245:764/73.
[103] Kuwata H, Yip TT, Tomita M, Hutchens TW. Direct evidence
of the generation in human stomach of an antimicrobial peptide
domain (lactoferricin) from ingested lactoferrin. Biochim Bio-
phys Acta 1998;1429:129/41.
[104] Ueta E, Tanida T, Osaki T. A novel bovine lactoferrin peptide,
FKCRRWQWRM, suppresses Candida cell growth and acti-
vates neutrophils. J Pept Res 2001;57:240/9.
[105] Ibrahim HR, Sugimoto Y, Aoki T. Ovotransferrin antimicrobial
peptide (OTAP-92) kills bacteria through a membrane damage
mechanism. Biochim Biophys Acta 2000;1523:196/205.
[106] Kalfa VC, Palmquist D, Ackermann MR, Brogden KA.
Suppression of Mannheimia (Pasteurella ) haemolytica serovar
1 infection in lambs by intrapulmonary administration of ovine
antimicrobial anionic peptide. Int J Antimicrob Agents
2001;17:505/10.
[107] Bensch LW, Raida M, Magert H-J, Schulz-Knappe P, For-
ssmann W-G. hBD-1: a novel b-defensin from human plasma.
FEBS Lett 1995;368:331/5.
K.A. Brogden et al. / International Journal of Antimicrobial Agents 22 (2003) 465/478 477
[108] Valore EV, Park CH, Quayle AJ, Wiles KR, McCray PB, Jr.,
Ganz T. Human beta-defensin-1: an antimicrobial peptide of
urogenital tissues. J Clin Invest 1998;101:1633/42.
[109] Schroder JM, Harder J. Human beta-defensin-2. Int J Biochem
Cell Biol 1999;31:645/51.
[110] Harder J, Bartels J, Christophers E, Schroder JM. Isolation and
characterization of human b-defensin-3, a novel human induci-
ble peptide antibiotic. J Biol Chem 2001;276:5707/13.
[111] Jia HP, Schutte BC, Schudy A, et al. Discovery of new human
(b-defensins using a genomics-based approach. Gene
2001;263:211/8.
[112] Garcia JR, Krause A, Schulz S, et al. Human b-defensin 4: a
novel inducible peptide with a specific salt- sensitive spectrum of
antimicrobial activity. FASEB J 2001;15:1819/21.
[113] Schutte BC, Mitros JP, Bartlett JA, Walters JD, Jia HP, Welsh
MJ, Casavant TL, McCray PB, Jr.. Discovery of five conserved
b-defensin gene clusters using a computational search strategy.
Proc Natl Acad Sci USA 2002;99:2129/33.
[114] Iwasa M, Kaito M, Ikoma J, et al. Lactoferrin inhibits hepatitis
C virus viremia in chronic hepatitis C patients with high viral
loads and HCV genotype 1b. Am J Gastroenterol 2002;97:766/
7.
[115] Tomita M, Wakabayashi H, Yamauchi K, Teraguchi S,
Hayasawa H. Bovine lactoferrin and lactoferricin derived from
milk: production and applications. Biochem Cell Biol
2002;80:109/12.
[116] van Berkel PH, Welling MM, Geerts M, et al. Large scale
production of recombinant human lactoferrin in the milk of
transgenic cows. Nat Biotechnol 2002;20:484/7.
[117] Yamauchi K, Toida T, Nishimura S, et al. 13-Week oral
repeated administration toxicity study of bovine lactoferrin in
rats. Food Chem Toxicol 2000;38:503/12.
[118] Zagulski T, Lipinski P, Zagulska A, Broniek S, Jarzabek Z.
Lactoferrin can protect mice against a lethal dose of Escherichia
coli in experimental infection in vivo. Br J Exp Pathol
1989;70:697/704.
[119] Lillard JW, Jr., Boyaka PN, Chertov O, Oppenheim JJ, McGhee
JR. Mechanisms for induction of acquired host immunity by
neutrophil peptide defensins. Proc Natl Acad Sci USA
1999;96:651/6.
[120] Brogden KA, Heidari M, Sacco RE, et al. Defensin-induced
adaptive immunity in mice and its potential in preventing
periodontal disease. Oral Microbiol Immunol 2003;18:95/9.
[121] Sitaram N, Subbalakshmi C, Krishnakumari V, Nagaraj R.
Identification of the region that plays an important role in
determining antibacterial activity of bovine seminalplasmin.
FEBS Lett 1997;400:289/92.
[122] Lehrer RI, Lichtenstein AK, Ganz T. Defensins: Antimicrobial
and cytotoxic peptides of mammalian cells. Annu Rev Immunol
1993;11:105/28.
[123] Tarver AP, Clark DP, Diamond G, et al. Enteric beta defensin:
molecular cloning and characterization of a gene with inducible
intestinal epithelial cell expression associated with Cryptospor-
idium parvum infection. Infect Immun 1998;66:1045/56.
[124] Skerlavaj B, Gennaro R, Bagella L, Merluzzi L, Risso A, Zanetti
M. Biological characterization of two novel cathelicidin-derived
peptides and identification of structural requirements for their
antimicrobial and cell lytic activities. J Biol Chem
1996;271:28375/81.
[125] Scocchi M, Romeo D, Zanetti M. Molecular cloning of Bac7, a
proline- and arginine-rich antimicrobial peptide from bovine
neutrophils. FEBS Lett 1994;352:197/200.
[126] Storici P, Del Sal G, Schneider C, Zanetti M. cDNA sequence
analysis of an antibiotic dodecapeptide from neutrophils. FEBS
Lett 1992;314:187/90.
[127] Romeo D, Skerlavaj B, Bolognesi M, Gennaro R. Structure and
bactericidal activity of an antibiotic dodecapeptide purified from
bovine neutrophils. J Biol Chem 1988;263:9573/5.
[128] Huttner KM, Lambeth MR, Burkin HR, Burkin DJ, Broad TE.
Localization and genomic organization of sheep antimicrobial
peptide genes. Gene 1998;206:85/91.
[129] Zhang G, Wu H, Shi J, Ganz T, Ross CR, Blecha F. Molecular
cloning and tissue expression of porcine b-defensin-1. FEBS Lett
1998;424:37/40.
[130] Storici P, Scocchi M, Tossi A, Gennaro R, Zanetti M. Chemical
synthesis and biological activity of a novel antibacterial peptide
deduced from a pig myeloid cDNA. FEBS Lett 1994;337:303/7.
[131] Tossi A, Scocchi M, Zanetti M, Storici P, Gennaro R. PMAP-
37, a novel antibacterial peptide from pig myeloid cells. cDNA
cloning, chemical synthesis and activity. Eur J Biochem
1995;228:941/6.
[132] Agerberth B, Lee JY, Bergman T, et al. Amino acid sequence of
PR-39. Isolation from pig intestine of a new member of the
family of proline-arginine-rich antibacterial peptides. Eur J
Biochem 1991;202:849/54.
[133] Tkachenko SB, Kokriakov VN, Ashmarin IP, Kubatiev AA.
Prophenin and PR39X*/novel antimicrobial leukocyte peptides
regulating functional activity of thrombocytes. Dokl Akad Nauk
1996;350:704/6.
[134] Zhao C, Ganz T, Lehrer RI. The structure of porcine protegrin
genes. FEBS Lett 1995;368:197/202.
[135] Couto MA, Harwig SS, Cullor JS, Hughes JP, Lehrer RI.
Identification of eNAP-1, an antimicrobial peptide from equine
neutrophils. Infect Immun 1992;60:3065/71.
[136] Brockus CW, Jackwood MW, Harmon BG. Characterization of
beta-defensin prepropeptide mRNA from chicken and turkey
bone marrow. Anim Genet 1998;29:283/9.
[137] Evans EW, Beach GG, Wunderlich J, Harmon BG. Isolation of
antimicrobial peptides from avian heterophils. J Leukoc Biol
1994;56:661/5.
[138] Zhao C, Liu L, Lehrer RI. Identification of a new member of the
protegrin family by cDNA cloning. FEBS Lett 1994;346:285/8.
[139] Zhao C, Nguyen T, Liu L, Shamova O, Brogden K, Lehrer RI.
Differential expression of caprine b-defensins in digestive and
respiratory tissues. Infect Immun 1999;67:6221/4.
[140] Christensen B, Fink J, Merrifield RB, Mauzerall D. Channel-
forming properties of cecropins and related model compounds
incorporated into planar lipid membranes. Proc Natl Acad Sci
USA 1988;85:5072/6.
[141] Kagan BL, Selsted ME, Ganz T, Lehrer RI. Antimicrobial
defensin peptides form voltage-dependent ion-permeable chan-
nels in planar lipid bilayer membranes. Proc Natl Acad Sci USA
1990;87:210/4.
K.A. Brogden et al. / International Journal of Antimicrobial Agents 22 (2003) 465/478478
